EUCTR2010-018485-24-CZ进行中（未招募）不适用
A multi-center, double-blind, randomized, placebo-controlled, dose-finding study in patients with active rheumatoid arthritis incompletely controlled on stable MTX doses to investigate efficacy and safety of SC BT061 - BT061 plus MTX in RA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Biotest AG
- 入组人数
- 128
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To participate in this trial, patients must meet all the following criteria:
- •1. Written informed consent
- •2. Patients of both gender with active rheumatoid arthritis (RA) according to 1987 revised ACR criteria with functional class I-III
- •3. Disease activity at screening (a, b, c) and baseline (a, b):
- •a.= 6 swollen joints on 66 joint count
- •b.= 6 tender joints on 68 joint count
- •c.= 1 out of 2 criteria:
- •i.erythrocyte sedimentation rate (ESR)
- •1. Male, = 50 years: = 23 mm/H
- •2. Male, > 50 years: = 30 mm/H
- •3. Female, = 50 years: = 30 mm/H
- •4. Female: > 50 years: = 45 mm/H
- •ii.CRP = 8 mg/L
- •4. Duration of RA = 12 months
- •5. Aged 18 years - 75 years (extremes included)
- •6. Body mass index (BMI) 18 kg/m2 - 32 kg/m2 (extremes included)
- •7. History of at least one traditional disease modifying anti-rheumatic drug (DMARD) with an inadequate response despite = 3 months of treatment
- •8. Oral or parenteral MTX treatment for = 3 months with an unchanged mode of application and stable MTX dose = 15 mg per week (or = 10 mg per week in case of MTX intolerance) and = the upper limit of the applicable Summary of Product Characteristics (SmPC) for at least 8 weeks prior to baseline
- •9. Patients could continue to receive = 7.5 mg daily of oral corticosteroids (prednisone or equivalent) at the same dose received prior to the study if dose was stable for = 6 weeks prior to baseline, if applicable
- •10. Patients could continue to receive non-steroidal antiinflammatory drugs (NSAIDs) at the same dose as received prior to the study if dose was stable for = 2 weeks prior to baseline, if applicable
- •11. No acute or clinically relevant abnormalities in electrocardiogram (ECG; 12-lead) at screening and baseline
- •12. The following blood test results must be fulfilled at screening:
- •a.Hemoglobin = 8.5 g/dL
- •b.Hematocrit > 30%
- •c.White blood cells (WBC) > 3.5*10E9 cells/L
- •d.Neutrophils = 1.5*10E9 cells/L
- •e.CD4 > 0.4*10E9 cells/L
- •f.B-cell count (CD19 count) > 75% of the lower limit of normal range (LLN)
- •g.Platelets = 150*10E9 cells/L
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 48
排除标准
- •1. Treatment with traditional DMARDs apart from MTX 12 weeks prior to baseline and for DMARD leflunomide 24 weeks (except specific leflunomide wash out procedure, i. e. 11 days with colestyramine or activated charcoal plus 30 days wash-out ) prior to baseline
- •2. Treatment with any biologics other than TNF-a inhibitors (e.g. abatacept, rituximab, tocilizumab, anakinra)
- •3. Treatment with any TNF-a inhibitor within 5 elimination half-lives (HLs) prior to baseline (e.g. 5 HLs certolizumab = 10 weeks, adalimumab = 10 weeks, etanercept = 3 weeks, infliximab = 7 weeks, golimumab = 10 weeks) and during the study
- •4. Clinical non-response to more than one previous TNF-a inhibitor treatment exceeding adequate treatment duration
- •5. Serious adverse drug reaction to previous biological treat-ment
- •6. Intra-articular, intramuscular, or intravenous corticosteroid treatment within 4 weeks prior to baseline and during the study
- •7. Previous therapy with CD4 monoclonal antibody (mab) BT061
- •8. Serum transaminases, alanine transaminase (ALAT) and/or aspartate transaminase (ASAT) > 2.5 fold ULN at screening
- •9. Bilirubin > 3 mg/dL at screening
- •10. Alkaline phosphatase > 2 fold ULN at screening
- •11. Urea nitrogen > 1.5 fold ULN at screening
- •12. Kidney insufficiency as defined by creatinine level > 1.5 mg/dl at screening
- •13. History of severe allergic or anaphylactic reaction to pro-teins of human origin (e.g. vaccination reaction, biological therapy)
- •14. Presence or history of malignancy within the previous 5 years (except completely resected squamous or basal cell carcinoma of the skin)
- •15. Presence or history of clinically significant major disease (e.g. severe heart/lung disease New York Heart Associa-tion [NYHA] Class = 3, autoimmune disease [apart from rheumatoid arthritis], acute uncontrolled hyper- or hypo-thyreoidism, severe uncontrolled hypo- or hypertension)
- •16. Serious local (e.g. abscess) or systemic (e.g. pneumonia, septicemia) infection or recurrent chronic infections within 6 weeks prior to screening visit or during the screening period
- •17. Any infection requiring antibiotic therapy by any route of administration within 2 weeks prior to baseline
- •18. Vaccination with live vaccines in the 12 weeks prior to the first administration of study drug and during the study or vaccination with inactivated vaccines in the first 4 weeks prior to administration of the study drug and during the study
- •19. Positive diagnosis for acute or chronic infections (i.e. Hepatitis C Virus [HCV], Hepatitis B Virus [HBV], Human Immunodeficiency Virus [HIV]) at Screening visit or history of previous chronic infection
- •20. Acute or clinically symptomatic Epstein-Barr Virus (EBV) (infectious mononucleosis) or Cytomegalovirus (CMV) infection
- •21. History of active tuberculosis and presence of latent or active tuberculosis
- •22. Presence or history of recurrent acute inflammatory joint disease other than RA
- •23. Known immune deficiency
- •24. Presence or history of lymphoproliferative disease, including lymphoma and lymphadenopathy
- •25. Presence or history of clinically significant drug or alcohol abuse
- •26. Joint surgery within 2 months prior to screening
- •27. The patient, planned to be enrolled, is an employee of any involved study investigator or any involved institution including the study sponsor
- •28. Pregnant or nursing women or women of childbearing potential (unless surgically sterile) who are not using two independent effective contraceptive methods du
研究者
相似试验
进行中（未招募）
1 期
A medical research study to evaluate the effects of ACT-246475 in adults with coronary artery disease.stable coronary artery diseaseMedDRA version: 20.0Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersEUCTR2017-003332-36-DKIdorsia Pharmaceuticals Ltd.324
进行中（未招募）
不适用
A study to assess efficacy and safety of selexipag in subjects with Raynaud's Phenomenon secondary to Systemic SclerosisEUCTR2014-000865-34-GBActelion Pharmaceuticals Ltd70
进行中（未招募）
不适用
A multi-center, double-blind, randomized, placebo-controlled, dose-ranging phase 2 study to investigate pharmacodynamics, safety, tolerability and pharmacokinetics of RO5073031 in patients with type 2 diabetes mellitus treated with a stable dose of metformin (BC20688)Type 2 diabetes mellitusMedDRA version: 8.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2006-004407-19-DEF. Hoffmann-La Roche Ltd264
进行中（未招募）
1 期
A medical research study to evaluate the effects of ACT-246475 in adults with coronary artery disease.stable coronary artery diseaseMedDRA version: 20.0Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersEUCTR2017-003332-36-NLIdorsia Pharmaceuticals Ltd.324
进行中（未招募）
1 期
Study to evaluate if macitentan is efficient, safe and tolerable enough to be used for treatment of Eisenmenger syndrome.MedDRA version: 18.0Level: PTClassification code 10058554Term: Eisenmenger's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEisenmenger SyndromeEUCTR2012-003335-33-CZActelion Pharmaceuticals Ltd.220